NEW HAVEN, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that it plans to release its financial results for the first quarter 2019 ended March 31, 2019 on Tuesday, May 7, 2019. BTI plans to hold a conference call at 8:30 AM Eastern Time on Tuesday, May 7, 2019 to discuss the financial results and provide a business update.
| CONFERENCE CALL & WEBCAST | ||
| Tuesday, May 7, 2019, 8:30 AM Eastern Time | ||
| Domestic: | 1-888-394-8218 | |
| International: | 1-323-794-2588 | |
| Conference ID: | 9482739 | |
| Webcast: | http://public.viavid.com/index.php?id=134360 | |
| Replay – Available through June 7, 2019 | ||
| Domestic: | 1-844-512-2921 | |
| International: | 1-412-317-6671 | |
| Conference ID: | 9482739 | |
About BioXcel Therapeutics, Inc. (BTI):
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxceltherapeutics.com.
Contact Information:
The Ruth Group for BTI:
Lee Roth / Janhavi Mohite
646-536-7012 / 7026
lroth@theruthgroup.com / jmohite@theruthgroup.com